Search Press releases Keywords From To 22 Sep 2005 European Commission Approves Use of UCB's Anti-Epileptic Keppra® as Adjunctive Therapy in Children Four Years of Age and Older with Partial-Onset Seizures Read More 15 Sep 2005 UCB'S ANTI-EPILECTIC KEPPRA® MEETS PRIMARY END-POINT IN MONOTHERAPY TRIAL Read More 26 Aug 2005 UCB Announces Divestment of Celltech Manufacturing Services - a UCB Subsidiary for Contract Manufacturing Read More 16 Aug 2005 UCB And Imclone Systems Enter Into Worldwide Partnership For Cdp-791, A Novel Investigational Therapy Targeting The Development Of Tumor Vasculature Read More 1 Aug 2005 UCB Reports Positive Opinion from EMEA for Paediatric Indication for Keppra® Read More 27 Jul 2005 UCB first half-year 2005 results including unaudited Half-Year Financial Report Read More Pagination First page Previous page Previous … Page 191 Page 192 Page 193 Page 194 Current page 195 Page 196 Page 197 Page 198 Page 199 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
